In this interview, Yousef Zakharia, MD, shares thoughts on the topic of expanding acute myeloid leukemia (AML) treatment. Dr. Zakharia discusses up-to-date AML treatments from combination trials such as VIALE-A, as well as mutation-directed personalized therapy for determining whether a patient will benefit from induction chemotherapy. Dr. Zakharia emphasizes the importance of molecular testing for clinicians to provide optimal treatment with the availability of such a wide range of available targeted therapies.

Click here to learn more.